NeuShen Therapeutics (纽欧申医药) is a clinical-stage biotechnology company headquartered in Shanghai, focused on developing new therapies for psychiatric and neurological disorders such as depression, schizophrenia, epilepsy and other central nervous system (CNS) diseases. Founded in 2022, it runs dual internal discovery platforms spanning small molecules and AAV-based gene therapy, with a pipeline of 10+ novel compounds including NS-041 (a KCNQ2/3 channel activator for focal epilepsy and depression) and NS-136 (an mAChR4 positive allosteric modulator for schizophrenia and Alzheimer-related psychosis).
1
Round
1
Industry
5
Tags
Sep 3, 2026
Latest raise
Funding activity · 1 round
Sep 3, 2026
$80M
Series B
NeuShen Therapeutics Secures $80M Series B Shanghai based clinical stage biotechnology company NeuShen Therapeutics (纽欧申医药) has raised an $80 million Series B…
Read articlePricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
